Articles related to ANTIBIOTICS

Extensively drug-resistant Shigella has increased in US surveillance, with sexual transmission emerging as an important route among some populations. Rising multidrug resistance may complicate treatment, although many infections remain self-limited.

The American Heart Association has updated infective endocarditis guidance to incorporate the 2023 Duke/ISCVID diagnostic criteria, advanced microbiologic diagnostics, contemporary imaging recommendations, and evolving antimicrobial treatment approaches while emphasizing multidisciplinary management.

A multisociety consensus paper outlines hospital-level strategies to improve sepsis outcomes, emphasizing diagnostic stewardship, antimicrobial optimization, surveillance, infection prevention, and multidisciplinary infrastructure while prioritizing interventions judged most feasible and impactful for broad implementation.

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

The FDA approved cefepime-zidebactam (Zaynich) for complicated UTI and pyelonephritis caused by susceptible gram-negative organisms. Approval followed phase 3 trial data showing higher rates of symptom and microbiologic resolution compared with meropenem in hospitalized adults.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.